[1] Xinhua Net. WHO: the total number of cases confirmed by COVID-19 in the world has reached 160813869[EB/OL]. (2021-05-15)[2021-06-16]. http://m.xinhuanet.com/2021-05/15/c_1127447840.htm. [2] National Health Commission, State Administration of traditional Chinese medicine. New coronavirus pneumonia diagnosis and treatment plan (Trial Eighth Edition)[J]. Chinese Journal of Clinical Infectious Diseases(中国临床感染病杂志), 2020,13(5): 321-328. [3] TIAN D, WANG L, GE ZR, et al.Present situation and prospect of antiviral treatments for COVID-19[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(3): 129-136. [4] SU Z, FAN SY.Potential therapeutic drug for corona virus disease 2019-lopinavir/ritonavir[J]. Clinical Medication Journal(临床药物治疗杂志), 2020, 18(2): 56-61. [5] YE XW, HE DL, CHENG WQ.Overview of the clinical application of lopinavir/ritonavir[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(23): 2496-2500. [6] CHEN BC, CHEN LS.2009 world’s best selling 200 kinds of prescription drugs(continued three)[J]. Herald of Medicine(医药导报), 2011, 30(4): 555. [7] HUANG Q. Academician Li Lanjuan’s team released: these two drugs can effectively inhibit COVID-19[EB/OL]. (2020-02-04)[2021-05-16]. http://www.cjrbapp.cjn.cn/p/157341.html. [8] CHEN J, LING Y, XI XH, et al.Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia[J]. Chinese Journal of Infectious Diseases(中华传染病杂志), 2020, 38(2): 86-89. [9] YANG MY, GAO YY, ZOU YJ, et al.Pharmacological recommendations on the off-label use of lopinavir/ritonavir for treatment of coronavirus disease 2019[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(6): 617-621. [10] CAO B, WANG Y, WEN D, et al.A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19[J]. The New England Journal of Medicine, 2020, 382(19): 1787-1799. [11] HUNG IFN, LUNG KC, TSO EYK, et al.Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, rando-mised, phase 2 trial[J]. The Lancet, 2020, 395(10238): 1695-1704. [12] LIM J, JEON S, SHIN HY, et al.Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR[J]. Journal of Korean Medical Science, 2020, 35(6): e79. [13] LYU LC, ZHENG LL, ZHAO YJ.Patent portfolio analysis of Kaletra based on patent bibliometrics[J]. Science Focus(科学观察), 2020, 15(5): 45-51. [14] CAI J, LI HX, LIU MY, et al.Safe use of lopinavir/ritonavir for COVID-19 based on literature analysis of adverse reactions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(6): 326-331. [15] QI ZB.Study on the synthesis of the core unit of ritonavir and lopinavir[D]. Hefei: Hefei University of Technology, 2008. [16] The United States Pharmacopeial Convention. U.S. Pharmacopeia National Formulary (USP42-NF37) Volume 2 [M]. Baltimore: United Book Press, 2019: 3880-3882. [17] Council of Europe. European Pharmacopoeia (EP10.0) Volume Ⅲ[M].Nӧrdlingen: Druckerei C. H. Beck, 2020: 3732-3736. [18] The British Pharmacopoeia Commission. British Pharmacopoeia(BP2021) Volume Ⅱ[M]. London: The Stationery Office, 2021: 824-827. [19] WHO Department of Essential Medicines and Health Products. The International Pharmacopoeia-Tenth Edition[EB/OL]. (2020-06-01)[2021-08-20]. https://digicollections.net/phint/2020/index.html#d/b.6.1.315. [20] BAI YF, ZHOU H, WU XJ, et al.A novel preparation method of ritonavir[J]. Liaoning Chemical Industry(辽宁化工), 2017, 46(1): 5-7. [21] Chinese Pharmacopoeia Commission.Pharmacopoeia of People’s Republic of Republic of China: Volume Ⅳ. 2020 edition(中华人民共和国药典:四部2020年版)[M]. Beijing: China Medical Science and Technology Press, 2020. [22] XIONG J, LIU Y, NING BM, et al.Study on stability of methylparaben and sodium methyl parahydroxybenzoate reference standards[J]. Drug Evaluation Research(药物评价研究), 2020, 43(6): 1065-1070. [23] XIONG J, YANG HX, WU JM, et al.Moisture sorption properties research of chemical reference substances based on dynamic vapor sorption analysis technology[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2015, 50(6): 532-535. [24] WHO. WHO stopped the branch trials of hydroxychloroquine and lopinavir / ritonavir[EB/OL]. (2020-07-05)[2021-06-18]. https://baijiahao.baidu.com/s?id=1671341468775052365&wfr=spider&for=pc. |